<DOC>
	<DOCNO>NCT00163475</DOCNO>
	<brief_summary>Bronchial asthma among world 's prevalent disease . Roflumilast novel , orally active , selective enzyme inhibitor ( phosphodiesterase 4 inhibitor ) , show effectiveness treatment asthma . The aim study compare effect roflumilast lung function , symptom , use rescue medication patient stable asthma . Roflumilast administer orally either morning even one dose level . The study duration consist baseline period ( 1 2 week ) treatment period ( 6 week ) . The study provide data safety , tolerability , effectiveness roflumilast .</brief_summary>
	<brief_title>Efficacy Safety Roflumilast Taken Morning Evening Patients With Stable Asthma ( 12 70 ) ( BY217/M2-015 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Main Written inform consent Diagnosis persistent bronchial asthma ( reference Global Initiative Asthma Guidelines 2002 ) Baseline FEV1 50 85 % patient either untreated receiving e.g . shortacting bronchodilator , DSCG , nedocromil , anticholinergic , longacting bronchodilator , theophylline/aminophylline , lipoxygenase inhibitor , leukotriene antagonist , alone combination Baseline FEV1 60 90 % patient receive 500 mcg BDPCFC ( equivalent ) and/or combination asthma medication mention No change asthma treatment 4 week prior baseline period Patients , exception asthma , good health Main Poorly control asthma : requirement course oral and/or parenteral glucocorticosteroids 4 week prior baseline , admission hospital asthma ( include treatment emergency room ) 4 week prior baseline period , asthma exacerbation last 4 week prior baseline period Patient use regularly &gt; 8 puffs/day rescue medication prior baseline History low airway infection last 4 week prior baseline period Diagnosis chronic obstructive pulmonary disease and/or relevant lung disease Heavy smoker : currently : &gt; 20 cigarettes/day and/or &gt; 10 pack year , exsmoker : smoking history â‰¥10 pack year Clinically relevant abnormal laboratory value suggest unknown disease require clinical evaluation Liver insufficiency ( Child Pugh A worse ) Active hepatitis Known infection HIV Diagnosis history cancer ( basal cell carcinoma ) recurrence within 5 year prior study start Alcohol and/or drug abuse Suspected hypersensitivity and/or contraindication ingredient study medication ( roflumilast ) rescue medication Pregnancy patient childbearing potential use reliable method contraception Patients able follow study procedure , e.g . due language problem , psychological disorder Suspected inability unwillingness comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Roflumilast</keyword>
</DOC>